

1 ***Pseudomonas aeruginosa* gene expression analysis using pangenome and**
2 **PAO1 reference genomes.**

3

4 BINP51, Bioinformatics: Master's Degree Project, 45 credits

5 Department of Biology, Lund University, Lund, Sweden.

6 Student: Yi Su, email: yi3446su-s@student.lu.se

7 Supervisor: Magnus Paulsson, email: magnus.paulsson@med.lu.se

8

9 **Abstract**

10 Development in sequencing technologies has made the analyses of genetic material much more
11 accessible. Processing sequenced data for an accurate analysis comes with its challenges,
12 especially with the studies in microbial in clinical *in vivo* samples where difficulties in the
13 collection of these samples for sequencing could lower the quality and contamination from the
14 human host which might affect the accuracy of downstream analysis. In this project, we use
15 RNA-seq and different reference genomes to look at the differential gene expression of
16 *Pseudomonas aeruginosa* (PA), one of the most prevalent species of bacterial pathogens in the
17 progression of chronic pulmonary diseases such as cystic fibrosis, due to its resistance to
18 antimicrobial treatment. In this project, we created a pangenome from 21 strains of PA and
19 explored the use of this, its subsets (core and soft-core gene sets) and a commonly used PA
20 genome (PAO1) as reference genomes. We compared some of the differences and similarities
21 in the results using the four gene sets, including for mapping transcripts while developing a
22 feasible pipeline to process raw sample reads from human sputum samples for differential
23 expression and gene ontology enrichment analysis. From the analyses, we have found
24 differentially expressed genes upregulated in *in vivo* samples were related to biofilm, which
25 plays a role in the difficulties in the treatment of PA infections, across the majority of the
26 various genome reference-based results.

27

28 **Introduction**

29 Cystic fibrosis (CF) is an example of an autosomal recessive disease, which is inherited from
30 mutations in the gene coding for cystic fibrosis transmembrane conductance regulator (CFTR)
31 protein. These proteins reside on the surface of airway epithelial cells and the serous cells of
32 the submucosal glands. Dysfunction or absence of CFTR leads to a complex complication of
33 chloride absorption and sodium hyperabsorption which can result in obstructions of the airways.
34 Accumulation of the airway surface liquid layer due to the thick and tenacious nature of the
35 secretion hamper the ability to clear bacteria from the lower airways and thus, allowing the
36 colonization of pathogens over time (Boucher, 2007).

37 The average estimated incidence of CF is between 1/3000 and 1/6000 births in the population
38 of European descent. There are multiple individual factors which are associated with poor
39 prognosis of CF, with lung function as the main predictor of survival. Other associated factors
40 include female sex, higher age of diagnosis and early colonization of *Pseudomonas aeruginosa*
41 (PA) (Scotet et al., 2020; Stephenson et al., 2017). Though bacterial infections may vary
42 between clinics and countries, the pathogens PA and *Staphylococcus aureus* are most
43 associated with CF (Uluer & Marty, 2014) .

44 *Pseudomonas aeruginosa* is a Gram-negative bacteria species which becomes more prevalent
45 with the progression of pulmonary disease in adults with CF and remains the most important
46 contributor to morbidity and mortality (Bhagirath et al., 2016). Once the bacterial colonization
47 is established at an early age, PA can become complex and difficult to eradicate due to its
48 genomic diversity and and adaptive resistance, despite high exposure to antibiotics (Rossi et
49 al., 2020; Tai et al., 2015). The relatively large genome of PA and switching in gene expression
50 allow the bacterial cells to survive challenges such as competition with other colonizers,
51 antibiotics, osmotic stress, and host immunity, and adapt to the CF lung environment (Wu et
52 al., 2014).

53 High-throughput sequencing technologies have been made much more accessible in recent
54 years and a few studies have been deploying this to study differentially expressed genes in PA
55 from *in vivo* clinical sputum samples and *in vitro* cultured isolates. Using a bioinformatics
56 approach, sequences from these samples can be analyzed for gene expression using a pipeline
57 of steps, resulting in a differential gene expression analysis in which the two environments are
58 compared to each other. Although obtaining RNA sequences comes with their own

59 complication that relates to sample collection, RNA extraction, library preparation and
60 sequencing, there are still ways to improve the quality and processing time of their analysis.

61 The pangenome was first introduced by Tettelin et al., 2005 in the studies of multiple microbial
62 strains, as the complete collective set of genes in the studied strains. Subsets from the
63 pangenome include a core genome which is defined as the set of genes present in all strains,
64 soft-core genome which includes genes that are present in most strains and an accessory
65 genome which contains the collection of genes that are only present in only a few strains.
66 Differential expression analysis presumes a common reference gene set to which the transcripts
67 generated during sequencing can be counted. The result of this analysis will be highly
68 dependent on the selected gene set, as only genes present in the selected reference gene set will
69 be included in the analysis. Using a gene set that is too limited will cause loss of information
70 and using an overly generous gene set will cause biases in the analysis as bacteria strains from
71 the same species can carry very diverse genes in their genome.

72 To enable further studies in which the transcriptomic response of PA cells growing at two
73 different environmental or clinical conditions, the bioinformatic analysis methods are
74 important as they influence the results and biological interpretation. This project aims to
75 develop a feasible pipeline and provide some insight into some of the different bioinformatic
76 approaches and tools in RNA-seq analysis for PA from *in vivo* clinical samples. With the steps
77 in the pipeline, we aim to pre-process raw read sequences from RNA-seq of clinical airway
78 samples and deplete them of human reads. We will then create a pan-genome which includes
79 core and soft-core genomes (Tettelin et al., 2005) using the 21 PA strains on the Kyoto
80 Encyclopedia of Genes and Genomes (KEGG) database with the tools Prokka (Seemann, 2014)
81 and Roary (Page et al., n.d.). Along with these 3 genomes, the widely used PAO1 reference
82 strain of PA will also be included in the analysis. We will then devise and test our approach by
83 mapping transcripts to the reference pangenomes using the pseudo aligner kallisto (Bray et al.,
84 2016); estimate the differential expression between publicly available transcripts from RNA-
85 seq experiments (Cornforth et al., 2018) using sequences from the SRA Archive in R with the
86 package DESeq2 (Love et al., 2014); conduct gene ontology analysis using PANTHER
87 classification system (Thomas et al., 2003).

88 The established pipeline will be possible to use in further studies of bacterial pathogens in
89 clinical airway samples compared to other environments, which may be relevant for detecting,
90 understanding and controlling bacterial infections in the future.

91

92 **Materials and Methods**

93 *Datasets*

94 The complete genome assemblies and protein data used in the creation of the pangenome
95 reference were downloaded from the NCBI genome database (Details in Supp table 1). *In vivo*
96 and *in vitro* clinical sample data were downloaded from the NCBI Sequence Read Archive
97 (SRA). PA isolates which were exposed to sub-MIC antimicrobials were chosen for the *in vitro*
98 samples. The *in vivo* samples were clinical sputum samples from cystic fibrosis patients who
99 were under antibiotic treatment. Accession numbers and details for the data used can be found
100 in Supp table 2.

101 *Pre-processing raw reads*

102 Quality of the reads was assessed using FASTQC/version 0.12.1 (Andrew., 2010) to ensure the
103 sequenced RNA data are viable to be used in the downstream analysis. Sequences were then
104 trimmed with TrimGalore/version0.4.4 for adapter contamination. The raw RNA reads were
105 collected and sequenced from the airways of clinical patients. As expected, there were large
106 numbers of human reads in the sequence, which were removed before counting the reads. By
107 removing human reads, we were able to process the files without the necessary security steps
108 required when working with sensitive human data and reduce the file sizes for faster processing.
109 The sample reads listed in the table was depleted of human reads using a combination of two
110 different methods of detecting human reads: taxonomy classification method with the software
111 Kraken2/version 2.1.1 (Wood et al., 2019) and alignment method software bowtie2/version
112 2.4.4 (Langmead & Salzberg, 2012).

113 The two-step method was used to ensure all human reads are removed from the *in vivo* samples.
114 Kraken2 software was used for the first step in detecting human reads. Using the *.kraken* file
115 outputs, the sequence ID for the reads that were not assigned by Kraken2 as '*Homo sapiens*'
116 were saved as a list and used with seqtk/version1.2 subseq command to extract non-human
117 reads from the sample reads files. The subsequent reads were then mapped to the human
118 genome GRCh37 from NCBI using bowtie2/version2.4.4. SAM flags were interpreted using
119 the Picard utility in the resulting SAM file output from bowtie2. SAMtools/version1.15.1 (Li

120 et al., 2009) was used to find reads that were flagged as unmapped. These were then extracted
121 into gzip compressed FASTQ files, completing the second step of removing human reads. A
122 second Kraken2 report was made for the final cleaned product. Once this method was
123 established, it was also applied in the decontamination of human reads in a parallel project
124 focusing on the *in vivo* gene expression of *Haemophilus influenzae* (Polland et al., 2023).

125 ***PA pan-genome creation***

126 The amount of plasticity in bacterial genomes creates a complication in the analysis based on
127 their genetic material. Considering the different strains and variations, it is often difficult to
128 find significant data with a reference genome based on one strain. Therefore, using a
129 pangenome as a reference would potentially provide a more complete set of genes to explore.

130 Moreover, a core genome can be extracted from the pan-genome. The core genome was here
131 defined as the set genes which were present in all 21 strains used to create the pangenome, and
132 the soft-core genome is defined by the set of genes which were only present in 20 strains.

133 The pan-genome creation was delimited to the 21 strains of PA with complete assemblies of
134 their genomes on the KEGG database. Genome assemblies were downloaded from NCBI and
135 created into a reference pan-genome using the tools Prokka/version1.14.16 and
136 Roary/version3.13.0. In the resulting pangenome, some genes could not be automatically
137 assigned a locus tag based on the commonly used nomenclature for PA. Instead, these were
138 labelled “*group_????*”, which limits the possibility of downstream analyses. A custom Python
139 script was generated to exchange “*group_????*” with NCBI locus tags using and the remaining
140 sequences that were not reannotated were searched with DIAMOND/version2.1.4 (Buchfink
141 et al., 2021) using the protein data from the 21 strains. From the final reannotated pangenome,
142 the core and soft-core genomes were extracted and the pangenome was explored using the
143 script provided with the Roary tool to generate statistics about the gene sets, a gene
144 presence/absence matrix and phylogenetic trees.

145 ***Pseudo-alignment of sample reads***

146 For this project, the pseudoaligner kallisto/version 0.48.0 was used in the pipeline to map the
147 sample reads to the core, soft-core, pangenome and PAO1 reference with bootstrap value of

148 100, and the parameters for single-end sequence mapping were used. The resulting kallisto
149 count data were used for downstream analysis.

150 ***Data normalization and exploration***

151 Tximport/version1.28.0 was used to import kallisto count data into R/version4.3.1 language
152 for statistical analysis. Counts were prefiltered where the genes with less than 10 counts across
153 all samples were not included in the downstream analysis. Regularized logarithmic method
154 rlog was chosen as the normalization method for visualization. The data was also explored with
155 unsupervised clustering: PCA and hierarchical clustering, which provided a rough overview of
156 the data before conducting differential expression analysis. This was also done to discover
157 potential outliers in the samples that may skew any of the downstream analysis. R packages
158 pheatmap/version1.0.12 was used to create the heatmaps, using the default Euclidean method
159 to create the sample-to-sample distance matrix.

160 ***Differential expression Analysis***

161 The study design was set to compare the differentially expression genes between *in vivo* sputum
162 samples from clinical patients under antibiotic treatment and *in vitro* lab-grown isolates which
163 were also treated with antibiotics. The differential expression analysis was done in R with the
164 use of R package DESeq2/version1.40.2. Significantly differentially expressed genes (DEGs)
165 were considered as having an absolute log₂ fold change > 1 and an adjusted p-value < 0.05.
166 Locus tags of significant DEGs were searched on the Pseudomonas database
167 pseudomonas.com.

168 ***Gene Ontology***


169 Gene ontology (GO) classification of all genes in the core, soft-core and pan genome were
170 explored using PANTHER release 17.0. Differentially expressed genes upregulated in the *in*
171 *vivo* sputum samples for core, soft-core, pangenome and PAO1 reference-based results were
172 analyzed with PANTHER Overrepresentation Test (Released 20230705) using the GO
173 biological process annotation set, which also tested with Fisher's Exact and correction for False
174 Discovery Rate (FDR). Only the results with FDR p-value < 0.05 were included.

175

176 **Results**

177 ***Pangenome***

178 The pangenome was created by the software tool Roary using the 21 strains of PA listed in the
179 KEGG database and the annotations from Prokka. The core genome and soft-core genome were
180 extracted from the pangenome and all three along with a PAO1 reference were used as reference
181 for the pseudo-alignment of sample reads. The pangenome consisted of a total of 13065
182 sequences, while the core and soft-core genome subsets from it had 3144 and 1799 sequences
183 respectively (Fig.1). Roary also defined the shell genome containing genes present between 19
184 and 3 strains and a cloud genome with genes present in 3 or less strains. The core genome
185 consisted of the genes that were present across all 21 strains while the soft-core consists of the
186 set of genes present in 20 strains, which were the number of strains for the different genomes,
187 as indicated by Roary. A large proportion of the pangenome were genes that were only present
188 in one or few of the strains used (Supp Fig.1).




189

190 **Fig.1** Pie chart illustrating the subsets of the pangenome generated from the 21 PA
191 strains in the KEGG database. Outside the chart the subset is specified (core, soft
score, shell and cloud genomes) and the number of strains that each the gene set is
shared by. The number inside the chart denotes the number of genes included in
each gene set.

192

193 The pangenome can also vary depending on the selection of strains used to create it. In the
194 pangenome created in this project, PA7, a commonly used reference strain was included but
195 there was also a large portion of genes that were not present in the core or soft-core genes
196 (Fig.2). The inclusion or exclusion of such strains can have a significant effect on the number
197 of resulting genes in different pangenome subsets.

198




199

200 **Fig.2** Matrix of the presence (blue) or absence of a gene (white) in the pangenome and a
201 phylogenetic tree of the 21 PA strains showing clustering of some strains such as the widely used
reference strain PAO1_107 with other PAO1 strains, and a distinct pattern of gene
absence/presence with strain PA7


202 To find out more about the predicted functions of the genes that were included in each gene set,
203 Gene ontology (GO) classification of the genes present in the different genomes was explored
204 under the PANTHER GO biological processes based on the locus tag of each gene; however, a
205 large proportion of the genes were unclassified by PANTHER. The percentage of unclassified
206 genes in each total number of genes in the 3 different genomes was 59.9% for pangenome,
207 53.6% for core and 68.2% and for soft-core genomes. Most of the genes that were classified

208 by PANTHER have the GO category for cellular process and metabolic process for all 3
209 genomes while the core genome had a higher percentage of these genes in its genome compared
210 to the pangenome and the soft-core genome. In contrast, genes under the GO category
211 biological adhesion were completely absent from the core genome gene set. No genes from the
212 soft-core genome (set of genes present in 20 strains) were categorized under the terms
213 “reproduction and reproductive process”. Higher percentages of genes for GO categories were
214 seen with the core which was likely due to the lower percentage of unclassified genes in its
215 genome compared to the other two gene sets (Fig.3A). To account for this, the results for
216 unclassified genes were filtered out, and the proportion of each GO category in the total
217 categorized genes was calculated and plotted in Fig3.B to present the differences between
218 reference genomes more accurately. Without including the unclassified genes, the proportion
219 of genes under each GO category between all 3 references was quite similar, except for
220 biological regulation which was lower in the core compared with the soft-core and pangenome
221 (Fig.3B).

A



B



223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245

Fig.3 Percentage of all genes (A) and genes given a GO-term (B) of the total number of genes in each gene set under the GO term for biological processes. Majority of genes can be seen among the categories cellular process and metabolic process, as well as localization, biological regulation, response to stimulus categories for all 3 genomes.

Pre-processing PA sample reads

To test the created bioinformatic pipeline, sample sequence reads downloaded from the SRA archive and were trimmed for adapter contamination before further decontamination processing. *In vivo* human sputum sample sequences naturally contained human reads, and these reads were depleted from the microbial sequences. The sequences were filtered twice, first with Kraken2 then with bowtie2 to detect human reads, and no human reads were detected in the resulting sequences by a second kraken report after the two filtering. For some of the samples, a substantial percentage (approx. 60%) of the total reads remained after the human reads removal process while most samples only have about 11-38% of their total reads remaining. (Table 1)

246 **Table 1** Number of reads for in vivo sputum samples for human reads decontamination process.

Sample/ SRA Accession	No. of reads						
	<i>Before human reads removal</i>				<i>After human reads removal</i>		
	<i>Total reads</i>	<i>Classified as human - Kraken2</i>	<i>Total remaining reads after 1st removal</i>	<i>Remaining reads classified as human - bowtie2</i>	<i>Total reads</i>	<i>Total (%) that remain</i>	<i>PA reads - Kraken2</i>
SRR6833347	89739225	29153461	60585764	7711681	52874083	58,92	37209
SRR6833344	53273099	42045528	11227571	5277978	5949593	11,17	240249
SRR6833345	80472332	55501895	24970437	15698029	9272408	11,52	226354
SRR6833346	40794451	18438229	22356222	13031965	9324257	22,86	30866
SRR6833349	70634441	26181099	44453342	17182543	27270799	38,61	1134684
SRR6833350	35200463	8902173	26298290	18731251	7567039	21,50	12325
SRR6833351	20062069	2550654	17511415	4968907	12542508	62,52	26775

247


248 **Differential expression analysis**

249 The count data output files from the kallisto pseudoalignment were imported into R using
 250 tximport. 4 types of reference genomes were used for the alignment: core, soft-core, pan and
 251 PAO1 reference genome, steps in the analyses were repeated for each category and the results
 252 were compared between them.

253 The raw counts were normalized with variance-stabilizing transformation (VST) and
 254 regularized logarithmic method, then plotted the standard deviation of the transformed data
 255 against the mean. The rlog method was chosen as the normalization method for visualization
 256 over VST since the standard deviation was seen as more constant for all 4 sets of count data
 257 (Supp fig.2).

258 For the exploration and visualization of the imported data, principal component analyses (PCA)
259 were performed for all 4 categories: core, soft-core, pan and PAO1 reference genome pseudo-
260 aligned count data. It can be inferred from the PCA plots that *in vitro* samples cluster closer
261 together than the *in vivo* sputum samples, and this is consistent in all 4 reference genome
262 categories. *In vivo* samples are expected to have high variability since there can be a lot of
263 contributing factors in differences in patients' co-morbidities, antibiotic treatment, genetics etc
264 compared to a controlled laboratory environment. One of the sputum samples was more distant
265 from the group, possibly due to low sequence quality or coverage.

266 Hierarchical clustering of samples visualized in heatmaps also shows the two groups, *in vivo*
267 and *in vitro* grouping together and the same *in vivo* sample clustering further from the *in vivo*
268 group, but still relatively closer compared to *in vitro* sample group. This pattern was also seen
269 in the data from other genome references.



270


271

272

273

274

Fig. 4 Principal component analysis (PCA) displaying PC1 and PC2 of samples for core (A), soft-core (B), pan (C) genome and PAO1 reference genome (D) showing that *in vitro* samples group together closely, compared to the *in vivo* sputum samples that were further apart.



275

276

277

278

Fig. 5 Sample distance heatmap of *in vivo* and *in vitro* counts in using core (A), soft-core (B), pan (C) and PAO1 reference genomes. Clearer visualization of one of the sputum samples clustered further away but still closer with samples in its group.

279 Using the different genomes, the number of significantly differentially expressed genes are
 280 1452 for core, 838 for soft-core, 3860 with pangenome and 2705 with PAO1 reference.
 281 Significantly differentially expressed genes are defined as having an absolute value of log2
 282 fold change (LFC) > 1 and p-adjusted value > 0.05 (table).

283

284 From the core genome reference counts, alginate biosynthesis related genes and other genes
 285 involved in biofilm formation are more prevalent with the highest LFC. These alginate
 286 biosynthesis related genes were not present in the other 3 datasets. Some of the upregulated
 287 soft-core DEGs can be found in the *psl* cluster (locus PA2231-PA2245) involved in *psl*
 288 polysaccharide synthesis, which is important in the biofilm structure of PA (Wei & Ma, 2013).
 289 These *psl* locus tags, such as PA2231, *pslA* were commonly found in the soft-core and PAO1
 290 reference DEGs. PA4107, a stress response and virulence modulator under high Calcium
 291 concentration, and PA4101 biofilm maturation regulator (Fan et al., 2021; Sarkisova et al.,
 292 2014) were the top DEGs in highest LFC for PAO1. Overall, more hypothetical proteins are
 293 found in the soft-core, pangenome and PAO1 reference compared to the core (Supp tables 3.1-
 294 3.4).

295 **Table 2** Top 10 significantly differentially expressed genes upregulated with highest LFC in *in*
 296 *vivo* sputum samples (with core genome reference)

Locus	Product	LFC	padj
PA3546	alginate biosynthesis protein AlgX	8.73	1.81e-15
PA3540	GDP-mannose 6-dehydrogenase	8.72	2.42e-28
PA3557	4-amino-4-deoxy-L-arabinose- phospho-UDP flippase subunit E	7.87	2.10e-15
PA4495	hypothetical protein	7.75	1.54e-34
PA3551	mannose-1-phosphate guanylyltransferase	7.68	3.06e-25
PA4883	hypothetical protein	7.64	8.49e-48
PA3601	50S ribosomal protein L31	7.54	1.49e-123
PA3541	glycosyl transferase	7.52	1.13e-27
PA4836	hypothetical protein	7.47	2.33e-41
PA3544	alginate biosynthesis protein AlgE	7.29	3.75e-20

297

298 **Gene Ontology Enrichment analysis**

299 Upregulated DEGS in the *in vivo* samples for all 4 reference-based results were analyzed for
 300 GO terms in biological processes using PANTHER. Only 3 GO terms were found with the
 301 upregulated DEGs for sputum samples in the core dataset, these terms were overrepresented
 302 and categorized under alginic acid metabolic process and monoatomic ion transport (Table 3).
 303 Interestingly, in both the results for the pan genome and PAO1 reference, GO terms related to
 304 iron transport were overrepresented while much more genes were underrepresented, including
 305 multiple terms related to metabolic processes and cellular biosynthetic processes. The majority
 306 of the GO terms for the soft-core, however, were unclassified by PANTHER and these were
 307 overrepresented, while several terms associated with metabolic and biosynthetic processes
 308 were, similarly with pan and PAO1, underrepresented (Table 4). All significantly
 309 overrepresented and underrepresented terms for each were stored in tables. (For a detailed list
 310 of GO, see Supp table 4.1-4.4.)

311 **Table 3** GO enriched terms for upregulated DEGS in *in vivo* samples (core)

GO biological process complete	PA-REFLIST (5564)	Count (882)	Expected	Over/Under represented (+/-)	Fold Enrichment	Raw P-value	FDR
alginic acid metabolic process (GO:0042120)	16	13	2.54	+	5.13	4.39E-05	9.76E-02
monoatomic cation transport (GO:0006812)	67	28	10.62	+	2.64	5.48E-05	4.07E-02
monoatomic ion transport (GO:0006811)	71	29	11.25	+	2.58	4.95E-05	5.51E-02

312

313 **Table 4** Top 5 GO terms with lowest raw p-values for upregulated DEGs in *in vivo* results

GO biological processes	Over(+)/ Under (-) represented
<i>Core</i> alginic acid metabolic process (GO:0042120)	+
monoatomic ion transport (GO:0006811)	+
monoatomic cation transport (GO:0006812)	+
-	
-	

Soft-core	cellular process (GO:0009987)	-
	macromolecule metabolic process (GO:0043170)	-
	Unclassified (UNCLASSIFIED)	+
	biological_process (GO:0008150)	-
	primary metabolic process (GO:0044238)	-
Pan	cellular nitrogen compound metabolic process (GO:0034641)	-
	nucleobase-containing compound metabolic process (GO:0006139)	-
	nitrogen compound metabolic process (GO:0006807)	-
	organonitrogen compound biosynthetic process (GO:1901566)	-
	translation (GO:0006412)	-
PAOI	cellular nitrogen compound metabolic process (GO:0034641)	-
	nucleobase-containing compound metabolic process (GO:0006139)	-
	nucleic acid metabolic process (GO:0090304)	-
	nitrogen compound metabolic process (GO:0006807)	-
	gene expression (GO:0010467)	-

314

315 Discussion

316 To have a better insight into the difference in gene expression of bacteria between *in vivo*
317 sputum samples of cystic fibrosis patients and cultured bacteria under controlled environments
318 when treated with antibiotics, we used an RNA-seq pipeline using different reference genomes
319 for transcript mapping, to analyze *Pseudomonas aeruginosa*, one of the prevalent bacterial
320 species in progressive pulmonary disease patients which show antimicrobial resistance towards
321 treatment.

322 A pangenome of 21 different PA strains was created for use as reference in the pseudoalignment
323 of the RNAs-seq samples. The PA pangenome is an open pangenome where the number of
324 genes continuously grow exponentially with new strains added. Therefore, to create a
325 pangenome that was feasible for the resources available for this project, only 21 strains with
326 complete genomes and annotations on the KEGG database were used, which include the most
327 well-studied strains. The choice of using a pangenome was considered because of the nature of
328 bacterial genetic material and with the aim to include genes shared by some of the different

329 strains that might not be present in a reference strain like PAO1. Genes in the core genome are
330 most likely to be comprised of more well annotated conservative genes for maintaining their
331 biological processes, therefore the soft-core genes were included in this project since
332 antimicrobial resistance and virulence genes might vary from strain to strain.

333 Obtaining RNA-seq data from *in vivo* samples can be challenging with the high standards
334 required for the extraction process of the genetic material in question, and the variation between
335 the samples can prove difficult for any downstream analysis that depends highly on the quality
336 of the sequences. The initial plan for this project involved using our own RNA sequences,
337 however, due to the low quality of these sequences in the samples, RNA sequences from the
338 SRA database were used instead. To improve the quality of the analysis, various bioinformatic
339 approaches have been developed and employed to process the data, including trimming and
340 human reads removal. Aggressive trimming of sequences can have a significant effect on gene
341 expression analysis especially on short reads sequences (Williams et al., 2016). The *in vivo*
342 sample sequences also had human reads naturally since the samples were sputum samples
343 collected from clinical patients. To decontaminate human reads from microbial reads for
344 downstream analysis and faster processing, the *in vivo* sample sequences were filtered. A
345 previous study showed that using two-step methods to remove human reads, produced some of
346 the better results in decontaminating microbial samples and different methods of detecting
347 human reads in microbial sequencing datasets have been tested by (Bush et al., 2020).
348 Detecting and removing human reads also has potential consequences. If certain genes in the
349 bacteria have high similarity with genes that are classified as human, in such a case this could
350 potentially cause a loss of data in the differential expression analysis between *in vivo* and *in*
351 *vitro* samples. Kraken2 was used to detect the final decontaminated sequences, in future studies,
352 the use of a third software tool or database may be recommended to confirm instead.

353 The tool kallisto pseudo-aligns transcripts to an annotated reference and includes the
354 quantification step of the counts, producing a raw count matrix which can then be imported
355 into DEG tools for analysis. The pseudo-alignment by kallisto does not require high computing
356 power, is much faster and the memory usage is low enough to be used on a personal laptop.
357 Some traditional aligners provide more data on the mapping, such as a splice junction aware
358 STAR and a quantification step would be required to produce count data. Since these details
359 are not required in the downstream analysis, a more lightweight tool like kallisto was used. A
360 previous comparison study of different alignment tools also showed that another pseudo-

361 alignment tool, salmon, would provide similar results (Schaarschmidt et al., 2020).
362 Normalization of raw counts is a staple for differential expression analysis and various methods
363 or approaches to normalization exists and their use depends on the nature of the data at hand.
364 In this project pipeline, the R package DESeq2 was used. The data was tested using different
365 transforms and regularized logarithmic method showed the most constant standard deviation
366 across all 4 sets of count data and has been shown to be generally performed well against other
367 methods (Love et al., 2014).

368 Among the top upregulated DEGs *in vivo* sputum samples, many were involved in biofilm.
369 Although, using different reference genomes found DEGs related to alginate synthesis biofilm
370 formation was prevalent in core, likewise for biofilm structure related in soft-core and PAO1
371 reference, and maturation related genes in PAO1. These genes that are involved in the biofilm
372 can be found in mucoid-type PA strains of cystic fibrosis patients and poses a difficulty in their
373 treatment due to antimicrobial resistance. Gene ontology enrichment analysis also showed
374 different results with different genome references. GO terms in metabolic and cellular
375 processes were underrepresented in pan and PAO1 genomes, alginic acid metabolism was
376 overrepresented in core and an overrepresentation of unclassified in soft-core. It makes sense
377 that vital functions for cell replication and metabolism are shared between all strains and are
378 part of the core genome. In future studies using a pangenome, the soft-core genome would
379 desirably include the core genome as well to provide more insight, since the definition for a
380 soft-core can be more flexible than only having a set of genes that were shared between 20
381 strains in this current project. Although only upregulated DEGs in *in vivo* samples were
382 analysed in this project, it would be important and recommended to also include
383 downregulated DEGs that potentially show the contrast between the cultured PA and *in vivo*
384 samples.

385 In conclusion, the choice of reference genomes to which the transcripts were pseudo-aligned
386 resulted in different DEGs upregulated in *in vivo* samples and with GO terms in biological
387 processes. There were distinct DEGs found in the core and soft-core datasets that may prove
388 insightful into reasons for antibiotic resistance due to biofilm or virulence. Results from the
389 pangenome and PAO1 reference showed similar GO terms in this project, it may be inferred
390 that using PAO1 reference would suffice if using a pangenome is not feasible. In future
391 pangenome studies, a core genome or an expanded soft-core genome may be used to discover
392 a more specific set of genes.

393 Transcriptomic analysis of PA in *in vivo* clinical samples can be a challenge, however there are
394 bioinformatic approaches where the quality of the analysis can be improved. Exploring the
395 options in using a pangenome compared to a single reference genome provided more insight
396 into the classifications of genes that may be expressed with using each different genome as a
397 reference for the mapping sample sequences. Quality control should be implemented but
398 aggressive trimming or filtering of sample sequences should only be used with caution of their
399 consequences. Pseudoalignment can be a feasible choice if computational power is limited to
400 smaller scales. The choice of tools can vary between different studies or research groups
401 depending on accessibility to computing resources and or familiarity with certain tools or
402 programming languages. Further studies comparing *in vivo* and *in vitro* samples using different
403 references would be worth exploring, since there are differences between DEGs found using
404 different genomes, and this would contribute insight to patterns in their expression and
405 treatment of PA in clinical settings.

406

407 **Acknowledgments**

408 I would like to thank the department and Magnus Paulsson for their insight into the fantastic
409 microbiological world of infectious disease and their unwavering encouragement and support
410 with this project.

411

412 **References**

413

- 414 Andrews, S. (2010). FastQC: A Quality Control Tool for High Throughput Sequence Data
415 [Online]. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>
- 416 Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., & Duan, K. (2016). Cystic
417 fibrosis lung environment and *Pseudomonas aeruginosa* infection. *BMC Pulmonary*
418 *Medicine*, *16*(1), 1–22. <https://doi.org/10.1186/S12890-016-0339-5/TABLES/2>
- 419 Boucher, R. C. (2007). Evidence for airway surface dehydration as the initiating event in CF
420 airway disease. *Journal of Internal Medicine*, *261*(1), 5–16.
421 <https://doi.org/10.1111/J.1365-2796.2006.01744.X>

422 Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Near-optimal probabilistic RNA-
423 seq quantification. *Nature Biotechnology* 2016 34:5, 34(5), 525–527.
424 <https://doi.org/10.1038/nbt.3519>

425 Buchfink, B., Reuter, K., & Drost, H. G. (2021). Sensitive protein alignments at tree-of-life
426 scale using DIAMOND. *Nature Methods* 2021 18:4, 18(4), 366–368.
427 <https://doi.org/10.1038/s41592-021-01101-x>

428 Bush, S. J., Connor, T. R., Peto, T. E. A., Crook, D. W., & Walker, A. S. (2020). Evaluation of
429 methods for detecting human reads in microbial sequencing datasets. *Microbial*
430 *Genomics*, 6(7), 5–18. <https://doi.org/10.1099/MGEN.0.000393>

431 Cornforth, D. M., Dees, J. L., Ibberson, C. B., Huse, H. K., Mathiesen, I. H., Kirketerp-
432 Møller, K., Wolcott, R. D., Rumbaugh, K. P., Bjarnsholt, T., & Whiteley, M. (2018).
433 *Pseudomonas aeruginosa* transcriptome during human infection. *Proceedings of the*
434 *National Academy of Sciences of the United States of America*, 115(22), E5125.
435 <https://doi.org/10.1073/PNAS.1717525115/-/DCSUPPLEMENTAL>

436 Fan, K., Cao, Q., & Lan, L. (2021). Genome-Wide Mapping Reveals Complex Regulatory
437 Activities of BfmR in *Pseudomonas aeruginosa*. *Microorganisms*, 9(3), 1–22.
438 <https://doi.org/10.3390/MICROORGANISMS9030485>

439 Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. *Nature*
440 *Methods* 2012 9:4, 9(4), 357–359. <https://doi.org/10.1038/nmeth.1923>

441 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G.,
442 & Durbin, R. (2009). The Sequence Alignment/Map format and SAMtools.
443 *Bioinformatics*, 25(16), 2078. <https://doi.org/10.1093/BIOINFORMATICS/BTP352>

444 Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and
445 dispersion for RNA-seq data with DESeq2. *Genome Biology*, 15(12), 1–21.
446 <https://doi.org/10.1186/S13059-014-0550-8/FIGURES/9>

447 Page, A. J., Cummins, C. A., Hunt, M., Wong, V. K., Reuter, S., Holden, M. T. G., Fookes,
448 M., Falush, D., Keane, J. A., & Parkhill, J. (n.d.). *Roary: rapid large-scale prokaryote*
449 *pan genome analysis*. <https://doi.org/10.1093/bioinformatics/btv421>

450 Polland, L., Rydén, H., Su, Y., Paulsson, M., (accepted: July 12, 2023). *In vivo gene*
451 *expression of Haemophilus influenzae during human pneumonia*. In press.

452 Rossi, E., La Rosa, R., Bartell, J. A., Marvig, R. L., Haagensen, J. A. J., Sommer, L. M.,
453 Molin, S., & Johansen, H. K. (2020). *Pseudomonas aeruginosa* adaptation and evolution
454 in patients with cystic fibrosis. *Nature Reviews Microbiology* 2020 19:5, 19(5), 331–
455 342. <https://doi.org/10.1038/s41579-020-00477-5>

456 Sarkisova, S. A., Lotlikar, S. R., Guragain, M., Kubat, R., Cloud, J., Franklin, M. J., &
457 Patrauchan, M. A. (2014). A *Pseudomonas aeruginosa* EF-Hand Protein, EfhP (PA4107),
458 Modulates Stress Responses and Virulence at High Calcium Concentration. *PLoS ONE*,
459 9(6), 98985. <https://doi.org/10.1371/JOURNAL.PONE.0098985>

460 Schaarschmidt, S., Fischer, A., Zuther, E., & Hincha, D. K. (2020). Evaluation of Seven
461 Different RNA-Seq Alignment Tools Based on Experimental Data from the Model Plant
462 *Arabidopsis thaliana*. *International Journal of Molecular Sciences*, 21(5).
463 <https://doi.org/10.3390/IJMS21051720>

464 Scotet, V., L'hostis, C., & Férec, C. (2020). The Changing Epidemiology of Cystic Fibrosis:
465 Incidence, Survival and Impact of the CFTR Gene Discovery. *Genes*, 11(6).
466 <https://doi.org/10.3390/GENES11060589>

467 Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics*, 30(14),
468 2068–2069. <https://doi.org/10.1093/BIOINFORMATICS/BTU153>

469 Stephenson, A. L., Stanojevic, S., Sykes, J., & Burgel, P. R. (2017). The changing
470 epidemiology and demography of cystic fibrosis. *La Presse Médicale*, 46(6), e87–e95.
471 <https://doi.org/10.1016/J.LPM.2017.04.012>

472 Tai, A. S., Bell, S. C., Kidd, T. J., Trembizki, E., Buckley, C., Ramsay, K. A., David, M.,
473 Wainwright, C. E., Grimwood, K., & Whiley, D. M. (2015). Genotypic Diversity within
474 a Single *Pseudomonas aeruginosa* Strain Commonly Shared by Australian Patients with
475 Cystic Fibrosis. *PloS One*, 10(12). <https://doi.org/10.1371/JOURNAL.PONE.0144022>

476 Tettelin, H., Massignani, V., Cieslewicz, M. J., Donati, C., Medini, D., Ward, N. L., Angiuoli,
477 S. V., Crabtree, J., Jones, A. L., Durkin, A. S., DeBoy, R. T., Davidsen, T. M., Mora, M.,
478 Scarselli, M., Margarit Y Ros, I., Peterson, J. D., Hauser, C. R., Sundaram, J. P., Nelson,
479 W. C., ... Fraser, C. M. (2005a). Genome analysis of multiple pathogenic isolates of
480 *Streptococcus agalactiae*: Implications for the microbial “pan-genome.” *Proceedings of*
481 *the National Academy of Sciences of the United States of America*, 102(39), 13950.
482 <https://doi.org/10.1073/PNAS.0506758102>

483 Tettelin, H., Massignani, V., Cieslewicz, M. J., Donati, C., Medini, D., Ward, N. L., Angiuoli,
484 S. V., Crabtree, J., Jones, A. L., Durkin, A. S., DeBoy, R. T., Davidsen, T. M., Mora, M.,
485 Scarselli, M., Margarit Y Ros, I., Peterson, J. D., Hauser, C. R., Sundaram, J. P., Nelson,
486 W. C., ... Fraser, C. M. (2005b). Genome analysis of multiple pathogenic isolates of
487 *Streptococcus agalactiae*: Implications for the microbial “pan-genome.” *Proceedings of*
488 *the National Academy of Sciences of the United States of America*, 102(39), 13950–
489 13955. https://doi.org/10.1073/PNAS.0506758102/SUPPL_FILE/06758TABLE2.PDF

490 Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., Diemer, K.,
491 Muruganujan, A., & Narechania, A. (2003). PANTHER: A library of protein families
492 and subfamilies indexed by function. *Genome Research*, 13(9), 2129–2141.
493 <https://doi.org/10.1101/gr.772403>

494 Uluer, A., & Marty, F. M. (2014). Cystic Fibrosis. *Mandell, Douglas, and Bennett's Principles
495 and Practice of Infectious Diseases, 1*, 874-885.e3. [https://doi.org/10.1016/B978-1-
4557-4801-3.00073-4](https://doi.org/10.1016/B978-1-
496 4557-4801-3.00073-4)

497 Wei, Q., & Ma, L. Z. (2013). Biofilm Matrix and Its Regulation in *Pseudomonas aeruginosa*.
498 *International Journal of Molecular Sciences 2013, Vol. 14, Pages 20983-21005*, 14(10),
499 20983–21005. <https://doi.org/10.3390/IJMS141020983>

500 Williams, C. R., Baccarella, A., Parrish, J. Z., & Kim, C. C. (2016). Trimming of sequence
501 reads alters RNA-Seq gene expression estimates. *BMC Bioinformatics*, 17(1), 1–13.
502 <https://doi.org/10.1186/S12859-016-0956-2/TABLES/2>

503 Wood, D. E., Lu, J., & Langmead, B. (2019). Improved metagenomic analysis with Kraken 2.
504 *Genome Biology*, 20(1), 1–13. <https://doi.org/10.1186/S13059-019-1891-0/FIGURES/2>

505 Wu, W., Jin, Y., Bai, F., & Jin, S. (2014). *Pseudomonas aeruginosa*. *Molecular Medical
506 Microbiology*, 753–767. <https://doi.org/10.1016/B978-0-12-397169-2.00041-X>

507

Supplementary Material

Supp table.1 PA strains used in the creation of the pangenome.


KEGG entry	Name and strain	RefSeq	GenBank	Pseudomonas.com AA file name
T00035	Pseudomonas aeruginosa PAO1	GCF_000006765.1	GCA_000006765.1	Pseudomonas_aeruginosa_PAO1_107.faa
T00401	Pseudomonas aeruginosa UCBPP-PA14	GCF_000014625.1	GCA_000014625.1	Pseudomonas_aeruginosa_UCBPP-PA14_109.faa
T00569	Pseudomonas aeruginosa PA7	GCF_000017205.1	GCA_000017205.1	Pseudomonas_aeruginosa_PA7_119.faa
T00818	Pseudomonas aeruginosa LESB58	GCF_000026645.1	GCA_000026645.1	Pseudomonas_aeruginosa_LESB58_125.faa
T01973	Pseudomonas aeruginosa M18	GCF_000226155.1	GCA_000226155.1	Pseudomonas_aeruginosa_M18_172.faa
T02161	Pseudomonas aeruginosa DK2	GCF_000271365.1	GCA_000271365.1	Pseudomonas_aeruginosa_DK2_174.faa
T01974	Pseudomonas aeruginosa NCGM2.S1	GCF_000284555.1	GCA_000284555.1	Pseudomonas_aeruginosa_NCGM2S1_173.faa
T02627	Pseudomonas aeruginosa B136-33	GCF_000359505.1	GCA_000359505.1	Pseudomonas_aeruginosa_B136-33_191.faa
T02711	Pseudomonas aeruginosa RP73	GCF_000414035.1	GCA_000414035.1	Pseudomonas_aeruginosa_RP73_192.faa
T03171	Pseudomonas aeruginosa PAO581	GCF_000468555.2	GCA_000468555.1	Pseudomonas_aeruginosa_PAO581_495.faa
T03098	Pseudomonas aeruginosa c7447m	GCF_000468935.2	GCA_000468935.1	Pseudomonas_aeruginosa_C7447m_494.faa
T03170	Pseudomonas aeruginosa PAO1-VE2	GCF_000484495.2	GCA_000484495.1	Pseudomonas_aeruginosa_PAO1-VE2_493.faa
T03097	Pseudomonas aeruginosa PAO1-VE13	GCF_000484545.2	GCA_000484545.1	Pseudomonas_aeruginosa_PAO1-VE13_492.faa
T02928	Pseudomonas aeruginosa PA1	GCF_000496605.2	GCA_000496605.2	Pseudomonas_aeruginosa_PA1_497.faa
T02929	Pseudomonas aeruginosa PA1R	GCF_000496645.1	GCA_000496645.1	Pseudomonas_aeruginosa_PA1R_496.faa

T02951	Pseudomonas aeruginosa MTB-1	GCF_000504045.1	GCA_000504045.1	Pseudomonas_aeruginosa_MTB-1_210.faa
T02970	Pseudomonas aeruginosa LES431	GCF_000508765.1	GCA_000508765.1	Pseudomonas_aeruginosa_LES431_489.faa
T02971	Pseudomonas aeruginosa SCV20265	GCF_000510305.1	GCA_000510305.1	Pseudomonas_aeruginosa_SCV20265_215.faa
T03035	Pseudomonas aeruginosa YL84	GCF_000524595.1	GCA_000524595.1	Pseudomonas_aeruginosa_YL84_2501.faa
T03031	Pseudomonas aeruginosa PA38182	GCF_000531435.1	GCA_000531435.1	Pseudomonas_aeruginosa_PA38182_7613.faa
T03789	Pseudomonas aeruginosa NCGM 1900	GCF_000829275.1	GCA_000829275.1	Pseudomonas_aeruginosa_NCGM1900_2620.faa


Supp table 2 Data on the sample raw reads

SRA accession	Description	Sample name
SRR6833347	Human sputum	SP01
SRR6833344	Human sputum	SP02
SRR6833345	Human sputum	SP03
SRR6833346	Human sputum	SP04
SRR6833349	Human sputum	SP05
SRR6833350	Human sputum	SP06
SRR6833351	Human sputum	SP07
SRR6833320	In vitro	INV01
SRR6833321	In vitro	INV02
SRR6833334	In vitro	INV03
SRR6833333	In vitro	INV04
SRR6833339	In vitro	INV05
SRR6833337	In vitro	INV06

Supp fig,1 Number of genes with each added genome in the pangenome



Supp fig.2. Standard deviation against mean plots for rlog (top) and vst (bottom) transformed data with core (A), soft-core (B), pangenome (C) and PAO1 (D) reference.



Supp table 3.1 Top 30 DEGs with highest LFC upregulated in *in vivo* samples (core)

Locus	Product	LFC	padj
PA3546	alginate biosynthesis protein AlgX	8.72735067459732	1.809181210769e-15
PA3540	GDP-mannose 6-dehydrogenase	8.72085014980398	2.41954663957224e-28

PA3557	4-amino-4-deoxy-L-arabinose-phospho-UDP flippase subunit E	7.86884925493475	2.09635079184614e-15
PA4495	hypothetical protein	7.74726583503276	1.54314164931535e-34
PA3551	mannose-1-phosphate guanylyltransferase	7.68192210917389	3.05514898658392e-25
PA4883	hypothetical protein	7.64312745859506	8.49102329151025e-48
PA3601	50S ribosomal protein L31	7.54142572063107	1.49302011578525e-123
PA3541	glycosyl transferase	7.51741477269646	1.12593717702441e-27
PA4836	hypothetical protein	7.46525470523055	2.33471862604233e-41
PA3544	alginate biosynthesis protein AlgE	7.29250654926474	3.74612471652051e-20
PA3549	alginate o-acetyltransferase AlgJ	7.2802003730797	1.23235414416003e-22
PA1318	cytochrome o ubiquinol oxidase subunit I	7.23693665274876	1.03956669065418e-20
PA3555	4-deoxy-4-formamido-L-arabinose-phospho-UDP deformylase	7.05915959932706	1.809181210769e-15
PA3284	hypothetical protein	6.97906306584287	1.25012508633195e-35
PA4837	TonB-dependent siderophore receptor family protein	6.93046874672158	9.78853986514742e-79
PA4884	hypothetical protein	6.90609029810302	3.26440349387906e-47
PA1924	hypothetical protein	6.89300156232974	2.0012452255878e-32
PA1922	TonB-dependent receptor	6.66089497707904	8.08382127754272e-51
PA3382	phosphonate ABC transporter permease	6.65498531053994	5.36133225841156e-19
PA3550	alginate o-acetyltransferase AlgF	6.62235211227699	1.21511985165431e-20
PA3556	4-amino-4-deoxy-L-arabinose transferase	6.545473863777	7.68436495597257e-25
PA3553	glycosyl transferase 2 family protein	6.52857865641282	2.08282670440422e-27
PA3887	Na ⁺ /H ⁺ antiporter NhaP	6.45159551315514	4.19892948769198e-18
PA5536	RNA polymerase-binding protein DksA	6.3855404402549	4.15170903471729e-60
PA3547	poly(beta-D-mannuronate) lyase	6.3669538184574	8.0805474507767e-18
PA5535	hypothetical protein	6.34043728925861	8.49763328290303e-81
PA3552	UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase	6.32404544006009	5.69006569666764e-36
PA0672	heme oxygenase	6.285688453289	4.90261952307695e-39
PA2504	hypothetical protein	6.2561013688627	1.2060526918772e-29
PA3542	Mannuronan synthase	6.24411553612907	1.91617775975478e-15

Supp table 3.2 Top 30 DEGs with highest LFC upregulated in *in vivo* samples (soft-core)

Locus	Product	LFC	padj
PA2231	undecaprenyl-phosphate glucose phosphotransferase	12.0661852257856	4.08467260041555e-39
PA2232	mannose-1-phosphate guanylyltransferase	10.350806429335	4.36752212980518e-25
PA2233	glycosyl transferase	10.2146877174039	3.96061406189783e-20
PA2230	hypothetical protein	9.71690029090534	1.70782640855982e-25

PA0737	hypothetical protein	9.65577758324045	1.52342097182293e-27
PA2234	sugar ABC transporter substrate-binding protein	9.21889250014078	4.89820147987707e-18
PA1343	hypothetical protein	8.42160254109762	4.36752212980518e-25
PA4110	beta-lactamase	7.60415608498913	8.18148009086465e-63
PA2382	L-lactate dehydrogenase	7.42594116748843	1.21474306507635e-17
PA2901	hypothetical protein	7.24097604269108	3.48294069201552e-18
PA4896	RNA polymerase sigma factor	7.00944432069077	3.83966369252187e-38
PA1921	hypothetical protein	6.77297804084437	2.56035823856146e-22
PA3281	hypothetical protein	6.59760119067687	8.36141725189782e-36
PA4773	S-adenosylmethionine decarboxylase proenzyme	6.55378981356946	6.0753422456519e-15
PA2426	extracytoplasmic-function sigma-70 factor	6.54339862039224	7.75902848380523e-66
PA3283	hypothetical protein	6.53304186693394	2.27193773510739e-37
PA2137	hypothetical protein	6.46731189057167	4.59396897507776e-09
PA3558	4-amino-4-deoxy-L-arabinose-phosphoundecaprenol flippase subunit ArnF	6.44580224579697	7.04127111068815e-08
PA4471	hypothetical protein	6.34265979503045	2.63877637837442e-49
PA2412	hypothetical protein	6.20613361559376	8.28955213357481e-55
PA2114	MFS transporter	6.08296292857876	1.22370519413049e-37
PA3282	hypothetical protein	6.00675970784409	6.01092390260704e-40
PA0806	hypothetical protein	5.90028023826561	1.65169578912543e-14
PA2562	hypothetical protein	5.69252134596141	6.1521600619956e-24
PA4206	efflux transporter	5.55291263699767	1.79008951082523e-08
PA0675	RNA polymerase sigma factor	5.50224707575977	9.53821983061741e-10
PA4122	hypothetical protein	5.49384151624025	1.05307831216081e-07
PA2413	diaminobutyrate--2-oxoglutarate aminotransferase	5.49253729425439	3.3474494394307e-32
PA3237	hypothetical protein	5.42481770860905	2.00569478991252e-24
PA2468	ECF sigma factor FoxI	5.32259016136384	3.3474494394307e-32

Supp table 3.3 Top 30 DEGs with highest LFC upregulated in *in vivo* samples (pangenome)

Locus	Product	LFC	padj
PALES_27001	MerR family transcriptional regulator	29.3658884342683	3.52906826988121e-28
PADK2_24120	hypothetical protein	25.5144437993583	3.42026532465315e-16
PADK2_24115	hypothetical protein	25.2408917642357	7.17103277254137e-16
PADK2_24105	hypothetical protein	25.2124373821647	7.76117644926574e-16
PADK2_14405	hypothetical protein	24.267345251804	9.67268936046437e-15
PADK2_10875	hypothetical protein	24.1878054936276	1.19391041575833e-14
PADK2_14450	phage integrase family protein	23.9270234233675	2.38800890540655e-14
PADK2_23935	hypothetical protein	23.5890974871985	5.72659984830355e-14
PADK2_14420	outer membrane efflux protein	23.440554037947	7.95951120674698e-14
PAM18_2643	TonB-dependent receptor	15.950825639483	2.68566574283341e-18
PADK2_08555	hypothetical protein	14.5508431064661	1.88253184530192e-11
PA4358	ferrous iron transport protein B	14.5182886912035	1.70834151895188e-35
SCV20265_1905	aminotransferase	14.2505581565393	4.4147977105467e-22
ILKJLEMH_02189	hypothetical protein	14.1696450375007	1.1346071648682e-12
PADK2_15970	hypothetical protein	13.9607091460233	1.36963872597201e-21
PALES_46081	hypothetical protein	13.7642275749314	4.4807381247146e-43
PADK2_08595	Glycosyltransferase	13.7533992601712	8.48508039970196e-21
PADK2_14190	DNA polymerase	13.6788193638487	1.15448902572632e-07
PALES_26991	ATPase P	13.5389641568962	1.30768051097447e-07
PADK2_11845	Copper-sensing two-component system response regulator CusR	13.4352397304597	1.87044039109347e-07
PADK2_10990	phage integrase	13.2807460243366	1.08549694073891e-31
PADK2_08550	UDP-N-acetyl-D-mannosaminuronate dehydrogenase	13.2614112006063	2.56718461655992e-18
PADK2_08570	hypothetical protein	13.1205150503612	5.73533372902833e-23
PA1S_RS25940	DNA-binding response regulator	13.1168250348165	4.31854991991221e-21
PSPA7_2862	cyclic peptide transporter	13.0746453235439	4.81714886460588e-18
PA4107	hypothetical protein	13.0294485476057	1.08870402771977e-18
PA4775	hypothetical protein	12.8452072138944	5.29637789118482e-21
PSPA7_4784	hypothetical protein	12.7790598333776	3.82108253107376e-25
PAM18_2607	acetyltransferase	12.7458987232445	2.30448742370938e-17
P62593	Beta-lactamase TEM	12.7261041793172	3.68725907844921e-34

Supp table 3.4 Top 30 DEGs with highest LFC upregulated in *in vivo* samples (PAO1 ref)

Locus	Product	LFC	padj
PA4107	EfhP	13.0510721578467	1.84511681741116e-15

PA4101	BfmR	12.5885038639685	8.25541655303288e-26
PA4106	conserved hypothetical protein	12.4546711175849	6.37242328847335e-12
PA2231	PslA	12.3623034402852	9.05474925716813e-42
PA4102	BfmS	12.2429604481771	4.52507527915493e-25
PA4104	conserved hypothetical protein	11.8259389904727	1.77545278611128e-13
PA3066	hypothetical protein	11.6397747498086	2.15953771097562e-32
PA0689	low-molecular-weight alkaline phosphatase B, LapB	11.5117816427607	2.75743801315848e-36
PA2220	probable transcriptional regulator	11.2847652625294	8.22857718616684e-23
PA5264	hypothetical protein	11.2485312767428	3.23684746793968e-27
PA5265	hypothetical protein	11.1703191860384	2.08657710034424e-34
PA4103	hypothetical protein	11.1333857787015	3.32163591230443e-10
PA4280.5	16S ribosomal RNA	11.1233426972329	0.000631846717268802
PA1471	hypothetical protein	11.006408809446	2.50529124908327e-24
PA2119	alcohol dehydrogenase (Zn-dependent)	10.8178956339079	1.93355213079538e-06
PA2232	PslB	10.6889133003309	2.75286921382355e-26
PA0100	hypothetical protein	10.6302615655605	1.65314275926554e-11
PA0498	hypothetical protein	10.621997847585	3.098864012077e-31
PA2233	PslC	10.6131772956741	7.07951192024871e-21
PA0497	hypothetical protein	10.3253697662804	6.85658606697171e-26
PA2456	hypothetical protein	10.3203107253949	1.84762790209762e-09
PA2771	diguanylate cyclase with a self-blocked I-site, Dcsbis	10.1676775779985	6.6346185760475e-29
PA0257	hypothetical protein	10.0955242130532	4.97563254032472e-28
PA3065	hypothetical protein	10.0867328714128	4.18517235428844e-23
PA2230	hypothetical protein	10.0662948986042	2.2525576145905e-27
PA4105	hypothetical protein	10.0374397971351	3.34156281218806e-10
PA3067	probable transcriptional regulator	9.98113228054582	3.47226998020911e-22
PA0737	hypothetical protein	9.86960275608147	2.9783305999352e-30
PA4195	putative amino acid ABC transporter substrate-binding protein	9.84591153196641	1.1579845470094e-25
PA2772	hypothetical protein	9.83938002348575	4.24397335618275e-18

Supp table 4.1 GO enrichment of upregulated DEGS in *in vivo* samples (core)

GO biological process	PA - REFLIST (5564)	Count (882)	Expe cted	Over/Under represented (+/-)	Fold Enrichment	Raw P-value	FD R
alginate metabolic process (GO:0042120)	16	13	2.54	+	5.13	4.39E-05	9.76 E-02
monoatomic ion transport (GO:0006811)	71	29	5	+	2.58	4.95E-05	5.51 E-02
monoatomic cation transport (GO:0006812)	67	28	2	+	2.64	5.48E-05	4.07 E-02

Supp table 4.2 GO enrichment of upregulated DEGS in *in vivo* samples (softcore)

GO biological process complete	PA - REFLIST (5564)	Count (882)	Exp ecte d	Over/Under represented (+/-)	Fold Enrich ment	Raw P- value	FD R
Unclassified (UNCLASSIFIED)	3254	330	278.96	+	1.18	4.67E-06	3.4603
biological_process (GO:0008150)	2310	147	198.04	-	.74	4.67E-06	2.6003
metabolic process (GO:0008152)	1293	77	110.85	-	.69	3.20E-04	3.2302
organic substance metabolic process (GO:0071704)	1217	71	104.33	-	.68	2.37E-04	3.1102
cellular process (GO:0009987)	1657	95	142.05	-	.67	3.42E-06	7.6003
nitrogen compound metabolic process (GO:0006807)	908	49	77.84	-	.63	3.18E-04	3.3702
primary metabolic process (GO:0044238)	971	48	83.24	-	.58	1.79E-05	7.9603
organic substance biosynthetic process (GO:1901576)	672	31	57.61	-	.54	1.37E-04	2.7702
biosynthetic process (GO:0009058)	681	31	58.38	-	.53	8.25E-05	2.0402
cellular biosynthetic process (GO:0044249)	573	25	49.12	-	.51	2.17E-04	3.2202
organonitrogen compound biosynthetic process (GO:1901566)	407	15	34.89	-	.43	2.40E-04	2.9602

								5.12
macromolecule metabolic process (GO:0043170)	518	17	1	-	.38	4.60E- 06	E- 03	3.99
nitrogen compound transport (GO:0071705)	256	7	5	-	.32	4.12E- 04	E- 02	1.43
small molecule biosynthetic process (GO:0044283)	232	4	9	-	.20	3.87E- 05	E- 02	3.31
gene expression (GO:0010467)	158	2	5	-	.15	2.97E- 04	E- 02	4.00
protein transport (GO:0015031)	130	1	4	-	.09	4.31E- 04	E- 02	3.42
establishment of protein localization (GO:0045184)	135	1	7	-	.09	2.92E- 04	E- 02	3.52
cellular macromolecule localization (GO:0070727)	142	1	7	-	.08	2.06E- 04	E- 02	3.27
protein localization (GO:0008104)	142	1	7	-	.08	2.06E- 04	E- 02	1.71
cellular localization (GO:0051641)	156	1	7	-	.07	6.15E- 05	E- 02	1.31
cellular component organization or biogenesis (GO:0071840)	161	1	0	-	.07	4.14E- 05	E- 02	3.15
amino acid biosynthetic process (GO:0008652)	111	0	9.52	-	< 0.01	2.27E- 04	E- 02	2.60
protein transmembrane transport (GO:0071806)	112	0	9.60	-	< 0.01	1.40E- 04	E- 02	4.36
alpha-amino acid biosynthetic process (GO:1901607)	99	0	8.49	-	< 0.01	4.89E- 04	E- 02	

cellular component biogenesis (GO:0044085)	119	0	0	-	10.2	< 0.01	9.39E-05	2.09	E-02
---	-----	---	---	---	------	--------	----------	------	------

Supp table 4.3 GO enrichment of upregulated DEGS in *in vivo* samples (pan)

GO biological process complete	PA - REFLIST (5564)	Coun t (882)	Expected	Over/U nder represe nted (+/-)	Fold Enrichme nt	Raw P- value	FDR
cellular nitrogen compound metabolic process (GO:0034641)	557	93	157.57	-	.59	2.23E-07	4.95
nucleobase-containing compound metabolic process (GO:0006139)	327	44	92.51	-	.48	3.10E-07	3.45
nitrogen compound metabolic process (GO:0006807)	908	178	256.86	-	.69	6.39E-07	4.74
organonitrogen compound biosynthetic process (GO:1901566)	407	64	115.14	-	.56	2.15E-06	1.20
translation (GO:0006412)	80	3	22.63	-	.13	3.47E-06	1.54
nucleic acid metabolic process (GO:0090304)	207	24	58.56	-	.41	3.57E-06	1.32
macromolecule metabolic process (GO:0043170)	518	91	146.54	-	.62	5.08E-06	1.61
heterocycle metabolic process (GO:0046483)	463	79	130.98	-	.60	7.12E-06	1.98
primary metabolic process (GO:0044238)	971	203	274.69	-	.74	1.31E-05	3.25
biosynthetic process (GO:0009058)	681	132	192.65	-	.69	1.54E-05	3.42
organic substance biosynthetic process (GO:1901576)	672	131	190.10	-	.69	2.10E-05	4.24
gene expression (GO:0010467)	158	17	44.70	-	.38	2.66E-05	4.92
carbohydrate derivative metabolic process (GO:1901135)	202	26	57.14	-	.45	3.13E-05	5.36

organic cyclic compound						1.29E-	2.06
metabolic process (GO:1901360)	501	95	141.73	-	.67	04	E-02
cellular biosynthetic process (GO:0044249)	573	113	162.10	-	.70	04	E-02
cellular component organization or biogenesis (GO:0071840)	161	20	45.55	-	.44	04	E-02
cellular nitrogen compound biosynthetic process (GO:0044271)	363	64	102.69	-	.62	04	E-02
transition metal ion transport (GO:0000041)	36	27	10.18	+	2.65	04	E-02
ncRNA metabolic process (GO:0034660)	75	5	21.22	-	.24	04	E-02
iron ion transport (GO:0006826)	30	24	8.49	+	2.83	04	E-02
O antigen metabolic process (GO:0046402)	35	0	9.90	-	< 0.01	04	E-02
O antigen biosynthetic process (GO:0009243)	35	0	9.90	-	< 0.01	04	E-02
cellular component biogenesis (GO:0044085)	119	13	33.66	-	.39	04	E-02
cellular aromatic compound metabolic process (GO:0006725)	469	90	132.68	-	.68	04	E-02
iron coordination entity transport (GO:1901678)	23	20	6.51	+	3.07	04	E-02
organonitrogen compound metabolic process (GO:1901564)	682	143	192.93	-	.74	04	E-02

Supp table 4.4 GO enrichment of upregulated DEGS in *in vivo* samples (PAO1 ref)

GO biological process complete	PA - REFLIST (5564)	Count (882)	Exp ected	Over/ Under represented (+/-)	Fold Enrichment	Raw P- value	FD R
cellular nitrogen compound metabolic process (GO:0034641)	557	93	161. 67	-	.58	5.30E- 08	1.18 E-04

nucleobase-containing compound metabolic process (GO:0006139)	327	43	94.9	-	.45	6.13E-08	6.82E-05
nucleic acid metabolic process (GO:0090304)	207	22	60.0	-	.37	3.10E-07	2.30E-04
nitrogen compound metabolic process (GO:0006807)	908	187	263.	-	.71	1.90E-06	1.06E-03
gene expression (GO:0010467)	158	15	45.8	-	.33	1.93E-06	8.58E-04
translation (GO:0006412)	80	3	23.2	-	.13	2.16E-06	8.03E-04
organonitrogen compound biosynthetic process (GO:1901566)	407	68	118.	-	.58	4.92E-06	1.56E-03
heterocycle metabolic process (GO:0046483)	463	81	134.	-	.60	5.22E-06	1.45E-03
cellular component organization or biogenesis (GO:0071840)	161	17	46.7	-	.36	6.91E-06	1.71E-03
cellular component biogenesis (GO:0044085)	119	10	34.5	-	.29	1.01E-05	2.26E-03
macromolecule metabolic process (GO:0043170)	518	96	150.	-	.64	1.31E-05	2.64E-03
biosynthetic process (GO:0009058)	681	136	197.	-	.69	1.52E-05	2.81E-03
organic substance biosynthetic process (GO:1901576)	672	135	195.	-	.69	2.07E-05	3.54E-03
primary metabolic process (GO:0044238)	971	214	281.	-	.76	5.33E-05	8.48E-03
carbohydrate derivative metabolic process (GO:1901135)	202	28	58.6	-	.48	7.47E-05	1.11E-02
cellular nitrogen compound biosynthetic process (GO:0044271)	363	64	105.	-	.61	7.68E-05	1.07E-02
cellular biosynthetic process (GO:0044249)	573	115	166.	-	.69	9.79E-05	1.28E-02
organic cyclic compound metabolic process (GO:1901360)	501	98	145.	-	.67	1.23E-04	1.52E-02
ncRNA metabolic process (GO:0034660)	75	5	21.7	-	.23	1.30E-04	1.53E-02
transition metal ion transport (GO:0000041)	36	28	10.4	+	2.68	1.34E-04	1.50E-02

iron ion transport (GO:0006826)	30	25	8.71	+	2.87	1.44E-04	1.52E-02
RNA processing (GO:0006396)	55	2	15.96	-	.13	1.61E-04	1.62E-02
iron coordination entity transport (GO:1901678)	23	21	6.68	+	3.15	2.05E-04	1.98E-02
cellular aromatic compound metabolic process (GO:0006725)	469	92	136.13	-	.68	2.24E-04	2.07E-02
ncRNA processing (GO:0034470)	53	2	15.38	-	.13	2.42E-04	2.15E-02
O antigen metabolic process (GO:0046402)	35	0	10.16	-	< 0.01	2.97E-04	2.54E-02
O antigen biosynthetic process (GO:0009243)	35	0	10.16	-	< 0.01	2.97E-04	2.45E-02
cellular component organization (GO:0016043)	121	14	35.12	-	.40	3.56E-04	2.83E-02
RNA metabolic process (GO:0016070)	144	19	41.80	-	.45	4.24E-04	3.25E-02
organelle organization (GO:0006996)	40	1	11.61	-	.09	5.51E-04	4.09E-02
cellular process (GO:0009987)	1657	411	480.96	-	.85	6.69E-04	4.80E-02